Levetiracetam Ameliorates L-DOPA-Induced Dyskinesia in Hemiparkinsonian Rats Inducing Critical Molecular Changes in the Striatum

L-DOPA-induced dyskinesias (LID) remain a major problem of long-term therapy of Parkinson’s disease. Levetiracetam, a new antiepileptic drug, has been shown to reduce LID, but the mechanisms underlying its effects are unknown. In this study, we assessed the effect of levetiracetam on key mediators o...

Full description

Bibliographic Details
Main Authors: Huan Du, Shuke Nie, Guiqin Chen, Kai Ma, Yan Xu, Zhentao Zhang, Stella M. Papa, Xuebing Cao
Format: Article
Language:English
Published: Hindawi Limited 2015-01-01
Series:Parkinson's Disease
Online Access:http://dx.doi.org/10.1155/2015/253878